This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Superior Vena Caval Obstruction (SVCO) - Management and Outcome

This study has been completed.
Princess Margaret Hospital, Canada
Information provided by:
University Health Network, Toronto Identifier:
First received: November 28, 2005
Last updated: August 12, 2010
Last verified: August 2010
All patients with symptomatic malignant SVCO deemed suitable for treatment either with radiation therapy or by stenting will be eligible. They will receive whichever treatment is deemed most clinically appropriate. Symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.

Condition Intervention Phase
Superior Vena Cava Syndrome Behavioral: Management and Outcome of SVCO Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Longitudinal Study of the Management and Outcome of Superior Vena Caval Obstruction (SVCO)

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Improvement in an index symptom at 4 weeks as recorded by a daily symptom diary

Secondary Outcome Measures:
  • Time to onset of palliation
  • Duration of symptom control
  • Survival
  • Number of days spent in hospital
  • Requirement for further treatment

Estimated Enrollment: 20
Study Start Date: October 2001
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Symptomatic clinical and radiological diagnosis of superior vena caval obstruction.
  • Underlying histological diagnosis deemed appropriate for palliative radiotherapy as treatment by investigator. Patients with chemosensitive tumours such as small cell lung cancer (both untreated and recurrent), lymphoma and testicular tumours, will be eligible if radiation is deemed to be appropriate treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00259584

Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Princess Margaret Hospital, Canada
Principal Investigator: Andrea Bezjak, MD Princess Margaret Hospital, Canada
  More Information Identifier: NCT00259584     History of Changes
Other Study ID Numbers: UHN REB 01-0770-C
Study First Received: November 28, 2005
Last Updated: August 12, 2010

Additional relevant MeSH terms:
Superior Vena Cava Syndrome
Vascular Diseases
Cardiovascular Diseases processed this record on July 27, 2017